CA2962081A1 - Exosomes utiles pour traiter une maladie de stockage lysosomal - Google Patents
Exosomes utiles pour traiter une maladie de stockage lysosomal Download PDFInfo
- Publication number
- CA2962081A1 CA2962081A1 CA2962081A CA2962081A CA2962081A1 CA 2962081 A1 CA2962081 A1 CA 2962081A1 CA 2962081 A CA2962081 A CA 2962081A CA 2962081 A CA2962081 A CA 2962081A CA 2962081 A1 CA2962081 A1 CA 2962081A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- exosomes
- lysosomal
- gaa
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462056125P | 2014-09-26 | 2014-09-26 | |
US62/056,125 | 2014-09-26 | ||
US201462082853P | 2014-11-21 | 2014-11-21 | |
US62/082,853 | 2014-11-21 | ||
US201562112940P | 2015-02-06 | 2015-02-06 | |
US62/112,940 | 2015-02-06 | ||
US201562211312P | 2015-08-28 | 2015-08-28 | |
US201562211204P | 2015-08-28 | 2015-08-28 | |
US62/211,204 | 2015-08-28 | ||
US62/211,312 | 2015-08-28 | ||
PCT/CA2015/050959 WO2016044947A1 (fr) | 2014-09-26 | 2015-09-25 | Exosomes utiles pour traiter une maladie de stockage lysosomal |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2962081A1 true CA2962081A1 (fr) | 2016-03-31 |
Family
ID=55580007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2962081A Abandoned CA2962081A1 (fr) | 2014-09-26 | 2015-09-25 | Exosomes utiles pour traiter une maladie de stockage lysosomal |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2962081A1 (fr) |
WO (1) | WO2016044947A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10702581B2 (en) | 2015-05-04 | 2020-07-07 | Ilias Biologics Inc. | Compositions containing protein loaded exosome and methods for preparing and delivering the same |
ES2926280T3 (es) * | 2015-12-08 | 2022-10-25 | Regeneron Pharma | Composiciones y métodos para internalizar enzimas |
GB2552460A (en) | 2016-07-11 | 2018-01-31 | Evox Therapeutics Ltd | CPP-Mediated EV Loading |
EP3356522A4 (fr) * | 2016-09-30 | 2019-03-27 | Cellex Life Sciences, Incorporated | Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants |
NZ760232A (en) | 2017-06-07 | 2023-05-26 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
CA3069123A1 (fr) * | 2017-07-06 | 2019-01-10 | Children's National Medical Center | Exosomes et procedes d'utilisation |
GB201718681D0 (en) * | 2017-11-13 | 2017-12-27 | Evox Therapeutics Ltd | Protein engineered extracellular vesicles |
GB201810301D0 (en) * | 2018-06-22 | 2018-08-08 | Evox Therapeutics Ltd | Combinatorial gene therapy |
AU2019312212B2 (en) * | 2018-07-24 | 2024-10-10 | Mayo Foundation For Medical Education And Research | Compositions and methods involving transforming extracellular vesicles |
KR102233530B1 (ko) * | 2018-11-22 | 2021-03-31 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
WO2020152298A1 (fr) | 2019-01-24 | 2020-07-30 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Procédé de production d'enzymes |
EP4117628A4 (fr) * | 2020-03-10 | 2024-04-10 | University of Cincinnati | Matériels et méthodes pour le traitement de la maladie de gaucher |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010031741A1 (en) * | 2000-02-17 | 2001-10-18 | Robin Ziegler | Methods for treatment of lysosomal storage diseases |
US9085778B2 (en) * | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
CN102497887A (zh) * | 2009-04-17 | 2012-06-13 | Isis创新公司 | 递送遗传物质的组合物 |
-
2015
- 2015-09-25 WO PCT/CA2015/050959 patent/WO2016044947A1/fr active Application Filing
- 2015-09-25 CA CA2962081A patent/CA2962081A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016044947A1 (fr) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2962081A1 (fr) | Exosomes utiles pour traiter une maladie de stockage lysosomal | |
Solomon et al. | Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives | |
TWI701332B (zh) | 用於治療溶酶體貯積病之腺相關病毒載體 | |
EP2532742B1 (fr) | Arylsulfatase A recombinante pour réduire les taux de galctosyl sulphatide | |
EP3519569B1 (fr) | Vecteurs viraux recombinés adéno-associés pour le traitement de la mucopolysaccharidose | |
US12116577B2 (en) | Codon-optimized human NPC1 genes for the treatment of Niemann-Pick type C1 deficiency and related conditions | |
EP2561069B1 (fr) | Enzyme des maladies lysosomales | |
EP2595650B1 (fr) | Procédé de fabrication de n-acetylgalactosamine-6-sulfatase hautement phosphorylé active humain, et son utilisation | |
TWI482625B (zh) | 重組人溶酶體酸性脂肪酶(lal)於治療人病患之溶酶體酸性脂肪酶缺乏症之用途 | |
TR201911293T4 (tr) | Asit sfingomiyelinaz yetmezliğinin tedavi edilmesine yönelik doz artırımlı enzim repleasman terapisi. | |
WO2017147719A1 (fr) | Procédé de traitement d'une neuropathie | |
WO2017147720A1 (fr) | Méthode de traitement d'un trouble du système nerveux central | |
US20230332112A1 (en) | Novel In Vitro and In Vivo Enrichment Strategy Targeting Lymphocytes Derived from Vector Transduced HSCS for Therapy of Disorders | |
WO2003068255A1 (fr) | Compositions et methodes visant a ameliorer le traitement de substitution enzymatique de maladies lysosomales | |
JP2004512313A (ja) | 血友病bを治療する遺伝子薬及びその調剤する方法 | |
WO2020152298A1 (fr) | Procédé de production d'enzymes | |
Roy | Cell disorders in lysosomal storage diseases | |
Matassini et al. | Carbohydrate‐Based Therapeutics for Lysosomal Storage Disorders | |
Borgida | Lysosomal Storage Diseases: How Gene-Targeted Therapies are Changing What is Treatable | |
Kho | Regulation of Reabsorption Process in Kidney by Neuraminidase 1: Implications in Nephrosialidosis | |
Gonzalez et al. | Genome Editing Tools for Lysosomal Storage Disorders | |
Priyadharshini et al. | Drug delivery systems in Krabbe disease—present and prospective approaches | |
Massaro | Intravenously administered gene therapy for neuronopathic Gaucher disease | |
AU2023212478A1 (en) | THERAPEUTIC mRNA | |
Motas | Gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (hunter syndrome) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |
Effective date: 20180925 |